BMO Capital analyst Evan Seigerman has maintained their bullish stance on GILD stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evan Seigerman has given his Buy rating due to a combination of factors that highlight Gilead Sciences’ strong performance and future potential. The recent launch of Yeztugo has been particularly impressive, with significant U.S. payer access achieved ahead of schedule and robust demand from various market segments. This success is complemented by Gilead’s solid execution in its HIV business, which has shown promising growth, leading to an increase in growth expectations for the year.
Additionally, Gilead’s legacy HIV prevention and treatment products, such as Descovy, have exceeded sales expectations, further bolstering the company’s performance. While there are challenges in the cell therapy segment, the potential for future growth in Gilead’s oncology franchise, particularly with Trodelvy and upcoming data from the iMMagine-1 study, provides a positive outlook. These factors, combined with Gilead’s current valuation relative to its peers, underpin Seigerman’s optimistic rating.
In another report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $135.00 price target.
GILD’s price has also changed moderately for the past six months – from $106.540 to $118.440, which is a 11.17% increase.